adiponectin analogue SR (ALY688-SR) / Allysta Pharma - LARVOL DELTA

The adiponectin-derived peptide ALY688 protects against the development of metabolic dysfunction-associated steatohepatitis. (PubMed, Clin Transl Sci) - "ALY688-SR may represent an effective approach in MASH treatment. Its mode of action involves inhibition of hepatic steatosis, inflammation, and fibrosis, possibly via canonical adiponectin-mediated signaling."

Journal • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor

Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF). (PubMed, Biomed Pharmacother) - "These results indicate that the adiponectin mimetic peptide ALY688 reduced PO-induced fibrosis, hypertrophy, inflammation and metabolic dysfunction and represents a promising therapeutic approach for treating HFrEF in a clinical setting."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • Metabolic Disorders • CCL3 • CCL4 • IL13 • IL17A • IL1B • IL5 • IL6 • POSTN • TIMP1 • TLR4

The slow-release adiponectin analogue ALY688-SR modifies early-stage disease development in the D2.mdx mouse model of Duchenne muscular dystrophy. (PubMed, Am J Physiol Cell Physiol) - "mdx mice partially prevents fibrosis and fibre type-specific atrophy and lowered force production in the more disease-apparent diaphragm in relation to lower mitochondrial redox stress and heterogeneous responses in certain inflammatory markers. These diverse muscle responses to adiponectin receptor agonism in early stages of DMD serve as a foundation for further mechanistic investigations."

Journal • Preclinical • Duchenne Muscular Dystrophy • Fibrosis • Genetic Disorders • Immunology • Inflammation • Muscular Atrophy • Muscular Dystrophy • Myositis • IL6 • TGFB1

ALY688-SR in Generally Healthy Overweight or Obese Adults (clinicaltrials.gov) - P1; N=8; Terminated; Sponsor: Allysta Pharmaceutical; N=50 ➔ 8; Recruiting ➔ Terminated; Inability to recruit due to COVID-19 pandemic restrictions

Clinical • Enrollment change • Trial termination • Genetic Disorders • Obesity